No description available.

No description available.

No description available.

Made available in DSpace on 2014-10-09T12:34:29Z (GMT). No. of bitstreams: 0 / Made available in DSpace on 2014-10-09T14:00:11Z (GMT). No. of bitstreams: 0 / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / Dissertação (Mestrado) / IPEN/D / Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP / FAPESP:09/11038-3

Made available in DSpace on 2014-10-09T12:34:29Z (GMT). No. of bitstreams: 0 / Made available in DSpace on 2014-10-09T14:00:11Z (GMT). No. of bitstreams: 0 / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / Os venenos de serpentes são complexas misturas com proteínas e peptídeos que apresentam uma variedade de atividades biológicas. Devido à riqueza de seus componentes, várias moléculas encontradas no veneno vêm sendo utilizadas com fins terapêuticos, como agentes anticoagulantes ou analgésicos. Recentemente, diversos estudos têm mostrado que substâncias oriundas do veneno de serpentes são eficazes agentes antitumorais tanto in vivo quanto in vitro. Os estudos referentes ao veneno de C. vegrandis são escassos, o que o torna um interessante objeto de investigação para o isolamento de possíveis biomoléculas com potencial antitumorigênico. No presente trabalho analisamos este veneno com o intuito de isolar novas toxinas com atividade antitumoral. Observamos atividade em varias frações que apresentaram imunoreatividade frente a um anticorpo anti-jararagina, sugerindo a presença de metaloproteinases que, sabidamente, apresentam atividade contra certos tipos de tumores. Pela análise de seqüenciamento de novo foram identificadas sequencias peptídicas idênticas as encontradas na espécie C.durissus durissus. Foi identificada também uma fração ativa de baixo peso molecular que acreditamos ser um análogo à crotoxina que já foi relatada neste veneno. / Dissertação (Mestrado) / IPEN/D / Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP / FAPESP:09/11038-3

no / The duocarmycins belong to a class of agent that has fascinated scientists for over four decades. Their exquisite potency, unique mechanism of action, and efficacy in multidrug-resistant tumour models makes them attractive to medicinal chemists and drug hunters. However, despite great advances in fine-tuning biological activity through structure-activity relationship studies (SARS), no duocarmycin-based therapeutic has reached clinical approval. In this review, we provide an overview of the most promising strategies currently used and include both tumour-targeted prodrug approaches and antibody-directed technologies.

No

Despite significant advances in cancer treatment, clinical response remains suboptimal and there is a continued requirement for improved chemotherapeutics. The attrition rate for new therapies is high, due principally to lack of in vivo efficacy and poor pharmacodynamics. Consequently better systems are required to determine in vivo preclinical efficiency and drug-target interactions. Engineering of cancer cells to express fluorescent or bioluminescent proteins, either endogenously or under the control of specific gene promoters, and their detection by noninvasive optical imaging has the potential to improve preclinical drug development. In this study, a panel of colorectal cancer cell lines were engineered to express fluorescent and luminescent proteins either constitutively or under control of gene-promoters for the DNA damage response gene p53 or the cell cycle regulator p21, both important pharmacodynamic sensors. These cell lines were characterised for their potential as in vivo models of primary and metastatic tumour therapy response, several showing significant potential. In addition to the development of these models, this study also addressed the pharmacokinetics of different luciferase substrates and identified optimal temporal and dose characteristics for each. Furthermore, a new application for bioluminescent imaging was developed and validated for use in preclinical evaluation of vascular disrupting agents, a new generation of cancer therapeutic. This study demonstrates that despite the dynamic and variable nature of fluorescent and bioluminescent imaging, reproducible results can be obtained if appropriate precautions are taken. The models developed herein will expedite cancer drug development whilst reducing and refining the use of animals in research.

Despite significant advances in cancer treatment, clinical response remains suboptimal and there is a continued requirement for improved chemotherapeutics. The attrition rate for new therapies is high, due principally to lack of in vivo efficacy and poor pharmacodynamics. Consequently better systems are required to determine in vivo preclinical efficiency and drug-target interactions. Engineering of cancer cells to express fluorescent or bioluminescent proteins, either endogenously or under the control of specific gene promoters, and their detection by noninvasive optical imaging has the potential to improve preclinical drug development. In this study, a panel of colorectal cancer cell lines were engineered to express fluorescent and luminescent proteins either constitutively or under control of gene-promoters for the DNA damage response gene p53 or the cell cycle regulator p21, both important pharmacodynamic sensors. These cell lines were characterised for their potential as in vivo models of primary and metastatic tumour therapy response, several showing significant potential. In addition to the development of these models, this study also addressed the pharmacokinetics of different luciferase substrates and identified optimal temporal and dose characteristics for each. Furthermore, a new application for bioluminescent imaging was developed and validated for use in preclinical evaluation of vascular disrupting agents, a new generation of cancer therapeutic. This study demonstrates that despite the dynamic and variable nature of fluorescent and bioluminescent imaging, reproducible results can be obtained if appropriate precautions are taken. The models developed herein will expedite cancer drug development whilst reducing and refining the use of animals in research.

Les nanotechnologies sont en train de révolutionner le domaine biomédical et plus particulièrement l’ingénierie tissulaire. Elles permettent aujourd’hui, non seulement de réparer mais aussi de régénérer les tissus. Cette nanomédecine régénérative est particulièrement adaptée pour répondre aux besoins importants liés aux maladies dégénératives, au vieillissement et aux traumatismes.Mon travail de thèse s’inscrit dans ce contexte et concerne l’élaboration de biomatériaux nanofibreux et microporeux actifs pour la régénération osseuse. Notre objectif essentiel est de réaliser un implant biodégradable nanostructuré permettant d’accélérer la réparation du tissu osseux. Notre stratégie innovante repose non seulement sur la mise en oeuvre de membranes par électrospinning mais aussi sur leur fonctionnalisation par des facteurs de croissance. Cette fonctionnalisation originale a consisté à enrober ces principes actifs dans des nanoréservoirs en utilisant la technique multicouche de polyélectrolytes. Des membranes de polycaprolactone (PCL) nanofibreuses et microporeuses ont été obtenues par électrospinning puis les fibres ont été enrobées de réservoirs contenant le facteur ostéoinducteur, la protéine morphogénique osseuse 2 (BMP-2). L’induction osseuse engendrée par ces réservoirs actifs a été mise en évidence in vitro après culture d’ostéoblastes humains primaires. Des expérimentations in vivo chez la souris ont permis de confirmer l’accélération de la régénération osseuse grâce à ces nanoréservoirs.Cette même stratégie a été validée in vivo, chez la souris, en utilisant des membranes de collagène d’origine animal commerciales utilisées en clinique. L’activité de ces membranes fonctionnalisées par des nanoréservoirs de BMP-2 est en cours d’analyse dans le cadre de tests précliniques pour une application maxillofaciale et parodontale. / Nanobiotechnology enables the emergence of entirely new classes of bioactive devices intended for targeted intracellular delivery for more efficiency and less toxicities. Tissue engineering is an interdisciplinary field that has attempted to implement a variety of processing methods for synthetic and natural polymers to fabricate tissue and organ regeneration scaffolds.We report here the first demonstration of bone regeneration by using a strategy based on a synthetic nanostructured membrane. This electrospun membrane is manufactured by using a FDA approved polymer, PCL, (polycaprolactone), and functionalized with nanoreservoirs of a growth factor (BMP-2). Our expected outcomes are the development of clinical applications in the field of tissue engineering and nanomedecine and particularly in bone regeneration.We propose the development of smart nanostructured active implants for regenerative medicine. Our strategycombines a synthetic biodegradable electrospun nanofibrous membrane based on PCL and a bioactive growth factor (BMP-2) entrapped into polymer nanoreservoirs built atop the nanofibers according to the layer-by-layer technology. In this study, by using primary osteoblasts, we have shown the capacity of these sophisticated implants to promote and accelerate not only in vitro bone induction; but also, in vivo, bone formation (mouse model).We have also validated our strategy, in vivo (mouse model), by using an already used in the clinic collagen membrane (animal origin) to accelerate bone regeneration. This unique strategy is used to entrap, protect and stabilize the therapeutic agent into polymer coating acting as nanoreservoirs enrobing fibers of membranes.